Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 40, Issue 8 (Aug 2002)

Issues

Evaluation of Two Modified Cardiac Troponin I Enzyme Immunoassays

Cornelia Haug / Max G. Bachem / Holger Woehrle / Martin Hetzel / Adolf Gruenert
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2002.145

Abstract

One of the major challenges for manufacturers of troponin immunoassays is to optimize the low-end of the assays because diagnostic and therapeutic interventions are based on decreasing cutpoints. Recently published consensus documents of the European Society of Cardiology and the American College of Cardiology recommended the 99th percentile of a reference control group as cut-off for increased troponin I levels and suggested that imprecision at the 99th percentile for each assay should be ≤10%. In this study, we have evaluated two newly modified cardiac troponin I (cTnI) enzyme immunoassays (Dimension® cTnI assay, Dade Behring, Germany and AIA-PACK cTnI 2nd-Gen, Eurogenetics Tosoh, Belgium). With both assays all measured cTnI values in plasma and serum samples of apparently healthy volunteers were within the reference ranges given by the manufacturers. Intra-assay coefficients of variation of cTnI concentrations above the 99th percentile (given by the manufacturers) were below 17% and decreased with increasing cTnI concentrations. In most samples, the AIA-PACK cTnI assay yielded higher results; however, a close correlation between both assays was observed. Both tests exhibit acceptable overall performance, but (especially the Dimension ® cTnI assay) do not yet meet the above-mentioned precision in the low-end assay range. These data emphasize the need for cTnI assay standardization and for further optimization at clinical decision levels.

About the article

Published Online: 2005-06-01

Published in Print: 2002-08-26


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2002.145.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Sangita M. Patil, Mangesh P. Bankar, Ramchandra K. Padalkar, Abhijit P. Pathak, Shital S. Ghodke, Sonali S. Bhagat, and Rahul A. Ghone
Journal of Indian College of Cardiology, 2014, Volume 4, Number 1, Page 8
[2]
Hannsjörg Baum, Anika Hinze, Peter Bartels, and Dieter Neumeier
Clinical Biochemistry, 2004, Volume 37, Number 12, Page 1079
[4]
Eberhard Gurr and Knut Leitz
Clinical Chemistry and Laboratory Medicine (CCLM), 2004, Volume 42, Number 9

Comments (0)

Please log in or register to comment.
Log in